Literature DB >> 1899093

Characterization of recombinant human Kirsten-ras (4B) p21 produced at high levels in Escherichia coli and insect baculovirus expression systems.

P N Lowe1, M J Page, S Bradley, S Rhodes, M Sydenham, H Paterson, R H Skinner.   

Abstract

Kirsten-ras is the oncogene most frequently activated in human tumors. Studies of its biological function have been limited by the nonavailability of significant amounts of the major protein product, Kirsten-ras (4B) p21. When expressed in Escherichia coli K12, the recombinant protein was rapidly cleaved upon cell lysis in the lysine-rich C terminus region, probably by the ompT protease. However, soluble full-length protein was obtained when the Kirsten-ras gene was expressed in an E. coli strain lacking the ompT gene, and also in a baculovirus/insect cell expression system. Additionally, the baculovirus/insect cell system produced about half of the Kirsten-ras protein in a membrane-associated form, which was post-translationally modified by polyisoprenylation and carboxyl-methylation. A C-terminally truncated form (residues 1-166) was also expressed at high levels in E. coli for x-ray crystallographic studies. The kinetics of GDP release and of GTP hydrolysis of the purified proteins are similar to those of the corresponding Harvey-ras proteins, though there are small differences in the relative affinities for GDP and GTP. Biological activity of full-length Kirsten Val-12 p21 was demonstrated by microinjection into Swiss 3T3 cells, resulting in morphological transformation, with a lower potency than that of Harvey Val-12 protein.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899093

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects.

Authors:  Christian W Johnson; Derion Reid; Jillian A Parker; Shores Salter; Ryan Knihtila; Petr Kuzmic; Carla Mattos
Journal:  J Biol Chem       Date:  2017-06-19       Impact factor: 5.157

2.  A stimulatory GDP/GTP exchange protein for smg p21 is active on the post-translationally processed form of c-Ki-ras p21 and rhoA p21.

Authors:  T Mizuno; K Kaibuchi; T Yamamoto; M Kawamura; T Sakoda; H Fujioka; Y Matsuura; Y Takai
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

Review 3.  New weapons to penetrate the armor: Novel reagents and assays developed at the NCI RAS Initiative to enable discovery of RAS therapeutics.

Authors:  Dominic Esposito; Andrew G Stephen; Thomas J Turbyville; Matthew Holderfield
Journal:  Semin Cancer Biol       Date:  2018-02-09       Impact factor: 15.707

4.  Microinjection of smg/rap1/Krev-1 p21 into Swiss 3T3 cells induces DNA synthesis and morphological changes.

Authors:  Y Yoshida; M Kawata; Y Miura; T Musha; T Sasaki; A Kikuchi; Y Takai
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

5.  Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions.

Authors:  William K Gillette; Dominic Esposito; Maria Abreu Blanco; Patrick Alexander; Lakshman Bindu; Cammi Bittner; Oleg Chertov; Peter H Frank; Carissa Grose; Jane E Jones; Zhaojing Meng; Shelley Perkins; Que Van; Rodolfo Ghirlando; Matthew Fivash; Dwight V Nissley; Frank McCormick; Matthew Holderfield; Andrew G Stephen
Journal:  Sci Rep       Date:  2015-11-02       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.